Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis

被引:25
作者
Ohtsuka, Tsutomu [1 ]
机构
[1] Dokkyo Med Univ Koshigaya Hosp, Dept Dermatol, Koshigaya, Saitama 3438555, Japan
关键词
high-sensitivity C-reactive protein; interleukin-6; systemic sclerosis; BLOOD MONONUCLEAR-CELLS; SOLUBLE IL-6 RECEPTOR; ONCOSTATIN M; SCLERODERMA; INFLAMMATION; ASSOCIATION; EXPRESSION; MONOCYTES; CYTOKINE;
D O I
10.1111/j.1346-8138.2010.00883.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Systemic sclerosis (SSc) is a systemic connective tissue disease of unknown etiology which presents immunological, vascular and connective tissue abnormalities. Serum interleukin (IL)-6 has been reported to be elevated in patients with SSc. Clinical and laboratory findings affecting the elevated level of high-sensitivity C-reactive protein (hs-CRP) were studied in patients with SSc. Clinical and laboratory findings also included serum IL-6 level. Thirty-nine SSc patients (male : female = 7:32, age 19-84 years, mean 62.6 years) were studied. hs-CRP was measured with a nephelometric assay. Serum IL-6 level was measured by enzyme-linked immunosorbent assay. The distributions of hs-CRP showed that 18 cases (46.2%) were not elevated (< 0.07 mg/dL), but 21 cases (53.8%) were (>= 0.07 mg/dL). Alkaline phosphatase and IL-6 in SSc patients with elevated hs-CRP (291 +/- 95 U/L, 3.23 +/- 2.74 pg/mL) were significantly more elevated than those in not elevated patients (221 +/- 75 U/L, 1.53 +/- 1.12 pg/mL) (P < 0.02, P < 0.01). The correlation between hs-CRP level and IL-6 level in SSc patients was 0.687 (P < 0.001). In conclusion, elevated serum IL-6 levels are reflected in elevated hs-CRP levels in SSc patients.
引用
收藏
页码:801 / 806
页数:6
相关论文
共 21 条
  • [1] PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA)
    不详
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (05): : 581 - 590
  • [2] Clinical correlations of potential activity markers in systemic sclerosis
    Becvár, R
    Stork, J
    Pesáková, V
    Stánová, A
    Hulejová, H
    Rysová, L
    Zatloukalová, A
    Zatloukal, P
    Jáchymová, M
    Pourová, AL
    [J]. AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 404 - 412
  • [3] Up regulated expression of tumour necrosis factor α converting enzyme in peripheral monocytes of patients with early systemic sclerosis
    Bohgaki, T
    Amasaki, Y
    Nishimura, N
    Bohgaki, M
    Yamashita, Y
    Nishio, M
    Sawada, K
    Jodo, S
    Atsumi, T
    Koike, T
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) : 1165 - 1173
  • [4] Tumor necrosis factor-α inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis
    Bosello, S
    De Santis, M
    Tolusso, B
    Zoli, A
    Ferraccioli, G
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (12) : 918 - 920
  • [5] INTERLEUKIN-6 SECRETION BY MONOCYTES AND ALVEOLAR MACROPHAGES IN SYSTEMIC-SCLEROSIS WITH LUNG INVOLVEMENT
    CRESTANI, B
    SETA, N
    DEBANDT, M
    SOLER, P
    ROLLAND, C
    DEHOUX, M
    BOUTTEN, A
    DOMBRET, MC
    PALAZZO, E
    KAHN, MF
    AUBIER, M
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (05) : 1260 - 1265
  • [6] PATHOLOGIC OBSERVATIONS IN SYSTEMIC SCLEROSIS (SCLERODERMA) - A STUDY OF 58 AUTOPSY CASES AND 58 MATCHED CONTROLS
    DANGELO, WA
    FRIES, JF
    MASI, AT
    SHULMAN, LE
    [J]. AMERICAN JOURNAL OF MEDICINE, 1969, 46 (03) : 428 - +
  • [7] Giacomelli R, 1996, J RHEUMATOL, V23, P291
  • [8] Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies
    Harris, ML
    Rosen, A
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (06) : 778 - 784
  • [9] Hasegawa M, 1998, J RHEUMATOL, V25, P308
  • [10] Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis
    Hasegawa, M
    Sato, S
    Ihn, H
    Takehara, K
    [J]. RHEUMATOLOGY, 1999, 38 (07) : 612 - 617